Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue

The goal of this single armed, non-randomized, pilot study is to demonstrate that placental tissue grafts are safe in living donor liver transplant and assess their impact on biliary outcomes in adults. MiMedx placental tissue grafts are registered with the FDA for homologous use in any location in the body as a protective barrier that supports the healing cascade, which is the use the investigators intend it for in this trial.

The main questions this study aims to answer are:

1. Can bile-duct reinforcement using MiMedx placental tissue grafting demonstrate equal-to-improved biliary complications in patients who are recipients of living donor liver transplant? 2. What are the rates of postoperative complications and outcomes of living donor liver transplant after using MiMedx placental tissue grafting?

Participants will:

1. undergo living donor liver transplant per standard procedures at Cleveland Clinic, including pre-procedure, post-procedure, and follow-up visits. 2. consent to the placement of MiMedx placental tissue graft around the biliary anastomosis during their liver transplant. 3. consent to allow the study team to perform a review of their medial records after each standard-of-care follow-up visit to assess presence of any biliary complications up to 1 year post-transplant.

• Post-operative Complication Rates [Срок оценки: 1 year post living donor liver transplant]
• Post-operative Hospital Length of Stay [Срок оценки: From date of transplant until date of discharge from hospital, assessed up to 365 days]
• Post-operative ICU Length of Stay [Срок оценки: From date of transplant until date of transfer out of ICU, assessed up to 365 days]
• Readmissions [Срок оценки: 1 year post living donor liver transplant]